Direct health-care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis-Reference-Cited by-同舟云学术

Direct health-care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis

Published:2017-12-28 Issue:1 Volume:33 Page:141-149
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Mak Lung-Yi¹^ORCID,Ng Siew C²,Wong Irene O L³,Li Michael K K⁴,Lo F H⁵,Wong Marc T L⁶,Leung C M⁷,Tsang Steven W C⁸,Chan K H⁹,Sze S F¹⁰,Shan Edwin H S¹¹,Lam Belsy C Y¹²,Hui Aric J¹³,Hung Ivan F N¹,Leung Wai K¹

Affiliation:

1. Department of Medicine; The University of Hong Kong, Queen Mary Hospital; Hong Kong

2. Institute of Digestive Disease; The Chinese University of Hong Kong; Hong Kong

3. School of Public Health; University of Hong Kong; Hong Kong

4. Department of Medicine; Tuen Mun Hospital; Hong Kong

5. Department of Medicine; United Christian Hospital; Hong Kong

6. Department of Medicine; Princess Margaret Hospital; Hong Kong

7. Department of Medicine; Pamela Youde Nethersole Eastern Hospital; Hong Kong

8. Department of Medicine; Tseung Kwan O Hospital; Hong Kong

9. Department of Medicine; North District Hospital; Hong Kong

10. Department of Medicine; Queen Elizabeth Hospital; Hong Kong

11. Department of Medicine; Caritas Medical Center; Hong Kong

12. Department of Medicine; Kwong Wah Hospital; Hong Kong

13. Department of Medicine; Alice Ho Miu Ling Nethersole Hospital; Hong Kong

Funder

Jessie and Thomas Tam Foundation

AbbVie pharmaceuticals, Hong Kong

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jgh.13817/fullpdf

Reference30 articles.

1. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn's and Colitis Epidemiology Study;Ng;Gastroenterology,2013

2. The economic burden of inflammatory bowel disease: clear problem, unclear solution;Stone;Dig. Dis. Sci.,2012

3. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital;Bernstein;Am. J. Gastroenterol.,2000

4. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases;Limsrivilai;Clin. Gastroenterol. Hepatol.,2017

5. Annual cost of care for Crohn's disease: a payer perspective;Feagan;Am. J. Gastroenterol.,2000

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Commensal bacteria promote azathioprine therapy failure in inflammatory bowel disease via decreasing 6-mercaptopurine bioavailability;Cell Reports Medicine;2023-08

2. Telemonitoring for patients with inflammatory bowel disease amid the COVID-19 pandemic—A cost-effectiveness analysis;PLOS ONE;2022-04-07

3. No increased risk of flare in ulcerative colitis patients in corticosteroid‐free remission after stopping 5‐aminosalicylic acid: A territory‐wide population‐based study;Journal of Gastroenterology and Hepatology;2022-04-06

4. The Magnitude of Crohn’s Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review;Inflammatory Bowel Diseases;2022-02-18

5. The clinical and economic burden of non-alcoholic steatohepatitis in the Middle East: behind the scene;Hepatology International;2021-06-18